CD79B based Bispecific ADC Development Service

T-cell recruiting bispecific antibodies and antibody fragments have been used to harness the cytotoxic potential of T cells for cancer treatment. CD79B, a component of the B cell receptor (BCR) complex, has been clinically validated by an anti-CD79B antibody-drug conjugate (ADC) as a safe and effective therapeutic target for B cell malignancies. As one of the leaders in antibody engineering, small molecular synthesis, and bio-conjugation, Creative Biolabs provides novel bispecific ADCs targeting CD79B. We believe our services will effectively save the time and cost of your project by taking advantage of our expertise and innovative technology platforms.

Background

The Overview of CD79B

CD79B is the B cell antigen receptor Ig-beta chain. Together with the Ig-alpha chain, also known as CD79A, this cell surface molecule forms a heterodimeric complex CD79 that associates with membrane immunoglobulin (mIgM). CD79B expression is exclusive to B lymphocytes and B cell lymphomas. Depending on the maturation state of the B cell, CD79B can be expressed either in the cytoplasm or on the cell surface. The CD79 receptor complex triggers numerous signaling pathways to mediate B cell development, maintenance, and activation. Most likely due to its function in class II antigen presentation, antibodies that bind CD79B rapidly internalize to the lysosomal compartment.

Fig.1 CD79B and the co-receptor CD19 act as an alternative B-cell signaling module.¹

ADC Therapeutics Targeting CD79B

CD79 was considered as a target for antibody therapy when it was first discovered. However, unconjugated anti-CD79 antibodies are not effective under most circumstances. Arming the antibodies with cytotoxic drugs could fulfill the promise of CD79 as a target for antibody therapy. Since CD79B comprise the heterodimeric signaling component of the B-cell receptor, it is an attractive target for the use of ADCs because they are B cell-specific, expressed in non-Hodgkin lymphomas (NHL), and are trafficked to a lysosomal-like compartment as part of antigen presentation. ADCs targeting CD79B were more effective than anti-CD79A ADCs and shown to be very efficacious in preclinical models with both cleavable (SPP-DM1 and MC-vc-PAB-MMAE) and uncleavable linkers. Based on preclinical data, anti-CD79B ADCs with appropriate linker and payload are promising therapeutics for the treatment of NHL.

Bispecific Antibody Targeting CD79B

The development of CD79B-based bispecific antibodies has made great progress in recent years. For example, anti-CD45 x CD79B, anti-CD32B x CD72B bispecific antibody can be potentially used in the treatment of autoimmune disease. Anti-CD3 x CD79B bispecific antibody could be designed for different B cell lymphoma therapy, and researches indicated that this bispecific antibody can induce T cell-dependent cytotoxicity towards CD79B expressing B cells.

Our Service

CD79B-based Bispecific ADCs Services

Based on our in-depth and comprehensive research, CD79B has the potential of being a highly effective bispecific ADC target, and drug conjugates targeting this receptor could have significant clinical potential. Creative Biolabs has been involved in the development of ADCs for many years and we are committed to completing your project with high quality. We have constructed different target combinations for CD79B-based bispecific ADCs development, including CD79B x CD3, CD79B x CD32B and CD79B x CD45. For any specified combination, we would like to discuss with you further to obtain the best solution. Please do not hesitate to contact us for more information.

Highlights

• Expertise in Antibody Engineering: Leveraging extensive experience in antibody engineering, small molecule synthesis, and bioconjugation, Creative Biolabs delivers high-quality CD79B-based bispecific ADCs tailored to specific research needs.
• Enhanced Efficacy: Our bispecific ADCs targeting CD79B demonstrate superior efficacy compared to unconjugated antibodies, utilizing cytotoxic drugs to maximize therapeutic outcomes in preclinical models.
• Optimized Internalization: Antibodies that bind CD79B rapidly internalize to the lysosomal compartment, enhancing the delivery and effectiveness of the cytotoxic payload, and improving treatment outcomes.
• Versatile Target Combinations: Creative Biolabs offers a range of target combinations for CD79B-based bispecific ADCs, including CD79B x CD3, CD79B x CD32B, and CD79B x CD45, providing flexible solutions for various therapeutic applications.
• Comprehensive Support: With a commitment to high-quality service, Creative Biolabs collaborates closely with clients to develop the most suitable CD79B-based bispecific ADCs, ensuring successful project outcomes and advancing cancer therapy research.

FAQ

1. Q: What makes CD79B an attractive target for bispecific ADCs in cancer therapy?

   A: CD79B, a component of the B cell receptor complex, is exclusively expressed on B lymphocytes and B cell lymphomas. Its ability to rapidly internalize to the lysosomal compartment upon antibody binding makes it an ideal target for bispecific ADCs, enhancing the delivery of cytotoxic drugs directly to cancer cells, particularly in non-Hodgkin lymphomas.

2. Q: How do CD79B-based bispecific ADCs improve the treatment of B cell malignancies?

   A: CD79B-based bispecific ADCs leverage the specific expression of CD79B on B cells and lymphomas to deliver cytotoxic drugs precisely to these cells. By targeting CD79B in combination with other antigens, such as CD3 or CD45, these ADCs can induce potent and selective anti-tumor activity, improving therapeutic outcomes in B cell malignancies.

3. Q: What are the key benefits of using Creative Biolabs' CD79B-based bispecific ADCs development services?

   A: Creative Biolabs offers a comprehensive suite of services for developing CD79B-based bispecific ADCs, including antibody engineering, small molecule synthesis, and bio-conjugation. Their expertise ensures the efficient design and construction of bispecific ADCs that are tailored to the specific needs of each project, saving time and reducing costs.

4. Q: How does Creative Biolabs optimize the development of CD79B-based bispecific ADCs for maximum efficacy?

   A: Creative Biolabs employs advanced technologies and in-depth research to optimize the selection of target combinations, linker strategies, and payloads for CD79B-based bispecific ADCs. This ensures that the ADCs are highly specific, stable, and effective in delivering therapeutic agents to B cell malignancies.

5. Q: What are some examples of CD79B-based bispecific ADCs that Creative Biolabs can develop?

   A: Creative Biolabs has developed various target combinations for CD79B-based bispecific ADCs, including CD79B x CD3, CD79B x CD32B, and CD79B x CD45. These combinations are designed to enhance the selective targeting and killing of B cells, providing powerful therapeutic options for conditions like B cell lymphomas and autoimmune diseases.

6. Q: How does the use of CD79B-based bispecific ADCs compare to traditional antibody therapies?

   A: CD79B-based bispecific ADCs offer several advantages over traditional antibody therapies, including enhanced specificity and potency. By delivering cytotoxic drugs directly to B cells via the CD79B receptor, these ADCs can achieve more effective tumor cell killing with reduced off-target effects, making them a superior therapeutic option.

Published Data

In this experiment, anti-CD22 and anti-CD79b antibody-drug conjugates (ADCs) were utilized to target proliferating B cells in non-Hodgkin's lymphoma (NHL). These ADCs were designed to deliver the potent anti-mitotic agent monomethyl auristatin E (MMAE) directly to B cells expressing CD22 and CD79b surface receptors. The study found that both ADCs led to significant depletion of B cells, particularly proliferating B cells (Ki-67+), in the blood and spleen of cynomolgus monkeys. This selective depletion was sustained longer with the ADCs compared to unconjugated antibodies, which supports the mechanism of action where the conjugated cytotoxic agent enhances the therapeutic efficacy by specifically targeting and killing proliferating B cells. The results highlight the potential of these ADCs as effective treatments for NHL, offering a targeted approach with a favorable safety profile compared to traditional chemotherapies.

Fig.2 Depletion of CD20+ B cells following administration of anti-CD22 or anti-CD79b ADCs.²

Featured Products

Anti-79b ADC